In its Common Drug Review (CDR) Update – Issue 133 published on February 13, 2018, CADTH announced revisions to its biosimilar and administrative review process. This update includes the following:
- Revisions to CADTH’s biosimilar process which creates a streamlined approach for biosimilar reviews through shorter timelines, fewer submission requirements and abbreviated biosimilar summary dossier templates;
- The announcement that application fees now apply to all CDR submissions and resubmissions irrespective of the notice of compliance / notice of compliance with conditions issuance date;
- A new fee guidance for pharmaceutical review programs which includes a new, reduced fee for the new biosimilar review process and an annual fee adjustment based on the Consumer Price Index; and
- New patient input templates for biosimilars, which offers specific prompts for biosimilar review.
Other updates include the issuance of new administrative forms, such as a revised pre-submission information requirements form for advanced notice, a revised application overview template and updated contact information.
Related Publications & Articles
-
Federal Court of Appeal dismisses appeal of SPRAVATO “innovative drug” decision
On November 10, 2021, the Minister of Health refused to reassess its decision that Janssen’s esketamine hydrochloride product (SPRAVATO) was not an “innovative drug” and therefore not entitled to data...Read More -
CIPO will not issue patents on July 9 or July 16
The Canadian Intellectual Property Office (CIPO) will be launching a new online portal for patent services, MyCIPO Patents, on July 15, 2024.Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More